Hyun Joon Park

Hyun Joon Park

Auto-generated profile, based on publicly available information

Hyun Joon Park

Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JJJinho Jung
Jinho Jung
HPHyun Joon Park
Hyun Joon Park
MJMinyoung Jung
Minyoung Jung
Jung J, et al. J Korean Med Sci. 2021 Jun;36(30):e193. https://doi.org/10.3346/jkms.2021.36.e193

31 December 2020 in Korean Journal of Transplantation
Verified
Journal Article
Open access
PDF file
HPHyun Joon Park
Hyun Joon Park
KSKwang Il Seo
Kwang Il Seo
YCYoungil Choi
Youngil Choi
Hyun Joon Park, Kwang Il Seo, Young Il Choi. Korean J Transplant 1999;0:. https://doi.org/10.4285/kjt.20.0017

30 June 2023 in Kosin Medical Journal
Verified
Journal Article
Open access
JJJoonho Jeong
Joonho Jeong
HPHyun Joon Park
Hyun Joon Park
Polycystic liver disease (PLD) is a hereditary disease characterized by the presence of 20 or more liver cysts. It is classified into three types: isolated autosomal dominant PLD, PLD with autosomal dominant polycystic kidney disease, and PLD with autosomal recessive polycystic kidney disease. Genetic alterations, ciliary dysfunction of the biliary epithelial cells, and aberrant cell signaling pathways are the main factors contributing to the pathophysiology of PLD; however, other complicated mechanisms are also involved. The Gigot and Schnelldorfer classifications are widely used in clinical practice. Most patients with PLD are asymptomatic; however, a few patients with advanced-stage disease may develop symptoms and complications that impair their quality of life and require treatment. The known treatment options for PLD are somatostatin analogues, aspiration with sclerotherapy, fenestration, hepatic resection, and liver transplantation. Although liver transplantation remains the only curative treatment for PLD, medical therapies are gradually being developed with the increasing knowledge of the disease’s pathophysiology. This review focuses on the clinical manifestations and diagnosis of PLD, as well as treatment strategies, to support clinicians regarding the clinical management of the disease.

1 January 2023 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
HYHee Jeong Yu
Hee Jeong Yu
JPJung-Gu Park
Jung-Gu Park
GJGyoo Sik Jung
Gyoo Sik Jung
KSKwang Il Seo
Kwang Il Seo
HPHyun Joon Park
Hyun Joon Park
JYJong Hyouk Yun
Jong Hyouk Yun
유희정, et al. J Korean Soc Radiol. 2023 Oct;84:e113. /Synapse/10.3348/jksr.2023.0063

30 June 2025 in Kosin Medical Journal
Verified
Journal Article
Open access
BKBangju Kim
Bangju Kim
HPHyun Joon Park
Hyun Joon Park
SLSang Uk Lee
Sang Uk Lee
KSKwang Il Seo
Kwang Il Seo
JLJung Wook Lee
Jung Wook Lee
JNJun Yeb Nam
Jun Yeb Nam
A combination of atezolizumab and bevacizumab is currently recommended for treating unresectable advanced-stage hepatocellular carcinoma (HCC), as it has demonstrated superior overall survival and progression-free survival compared to sorafenib. However, concerns have been raised regarding serious adverse events associated with bevacizumab, such as gastrointestinal perforation, fistula, hemorrhage, and arterial thromboembolism. In particular, patients with liver cirrhosis (LC) show an increased risk of variceal bleeding. However, brain hemorrhage associated with the use of bevacizumab in patients with HCC and LC is extremely rare. We encountered two cases of brain hemorrhage in patients with HCC and LC who underwent treatment with atezolizumab and bevacizumab. One patient had no history of hypertension, while the other patient had hypertension that was well-controlled with medication and an unruptured brain aneurysm located on the right side of the anterior communicating artery. Both patients experienced brain hemorrhage after two treatment cycles of atezolizumab with bevacizumab. One patient died due to brain hemorrhage, while the other patient recovered from subarachnoid hemorrhage with successful coil embolization. This case report suggests that if a patient has any high-risk factors associated with brain hemorrhage, physicians should thoroughly consider alternative treatment options for advanced HCC, as brain hemorrhage could be fatal.

1 January 2026 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HPHyun Joon Park
Hyun Joon Park
JJJin Kyu Jung
Jin Kyu Jung
JNJeonghwan Noh
Jeonghwan Noh
YKYeonsu Kim
Yeonsu Kim
SLSang Uk Lee
Sang Uk Lee
KSKwang Il Seo
Kwang Il Seo
Park HJ, et al. J Korean Med Sci. 2026 May;41:e134. https://doi.org/10.3346/jkms.2026.41.e134